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Treatment  of cutaneous  leishmaniasis  remains  limited  to  a few available  options.  Recent  studies  showed
in vitro  antileishmanial  activity  of  (−) mammea  A/BB,  a coumarin  isolated  from  leaves  of  Calophyllum
brasiliense.  Moreover,  the  dichloromethane  crude  extract  and  hexane  fraction  from  this  plant  demon-
strated  in  vivo  activity  in  mice  infected  with  Leishmania  amazonensis.  We  evaluated  the  antileishmanial
activity  of (−)  mammea  A/BB  in  the  L.  amazonensis  BALB/c  mice  model.  The  animals  were  given  intramus-
cular  and  topical  treatment  with  (−)  mammea  A/BB  for 30  consecutive  days.  The results  demonstrated
that  18  mg/kg/d  intramuscularly  or  0.2%  topically  of  (−)  mammea  A/BB  signiﬁcantly  reduced  the  size
of  skin  lesions  in  footpads  of  mice  compared  with  those  in the  control  group  (p  < 0.05).  The  activity  of
Glucantime® (corresponding  to 27  mg/kg/d  of pentavalent  antimony)  administered  intramuscularly  was
similar to  that  of  (−)  mammea  A/BB  (p  < 0.05)  by  both  routes  of  administration.  The  histopathological
evaluation  showed  no changes  in  the  organs  analyzed.  These  results  indicate  that  the  coumarin  obtained
from  C. brasiliense  is  the  antileishmanially  active  compound  and  can  be used  to control  the  development
of  cutaneous  leishmaniasis  lesions  caused  by  L.  amazonensis.
 ntroduction
Cutaneous leishmaniasis (CL) usually produces skin ulcers on
he exposed parts of the body and they leave permanent scars
nd may  cause serious disability (WHO  2011). In the Americas,
L is caused mainly by Leishmania (Viannia) braziliensis,  Leishma-
ia (Leishmania) amazonensis, and Leishmania (Viannia) guyanensis,
nd requires treatment (Gonc¸ alves et al. 2005). Intralesional or
ystemic antiparasitic pentavalent antimonials such as sodium sti-
ogluconate or meglumine antimoniate are the gold standard for
he treatment of these diseases. Intramuscular pentamidine may  be
sed in individuals intolerant to antimonial treatment or in cases
f systemic antimony resistance. Liposomal amphotericin B may  be
n alternative to antimonials for the treatment of CL with mucosal
nvolvement in South America. Oral miltefosine is promising for
he treatment of CL, but more studies are needed to evaluate its
∗ Corresponding author at: Departamento de Ciências Básicas da Saúde, Labo-
atório de Inovac¸ ão Tecnológica no Desenvolvimento de Fármacos e Cosméticos,
loco B-08, Universidade Estadual de Maringá, Av. Colombo 5790, CEP 87020-900,
aringá, Paraná, Brazil. Tel.: +55 44 3011 5012; fax: +55 44 3011 5046.
E-mail addresses: cvnakamura@uem.br,
vnakamura@gmail.com (C.V. Nakamura).
944-7113     © 2012 Elsevier GmbH.  
ttp://dx.doi.org/10.1016/j.phymed.2012.08.001
Open access under the Elsevier OA license. © 2012 Elsevier GmbH. 
effectiveness against different species of Leishmania (Minodier and
Parola 2007; Mitropoulos et al. 2010).
Much emphasis has been given to the development of alterna-
tive therapeutic approaches. A compound for topical treatment of
CL is an attractive option because it would be easy to apply and can
avoid the problems with systemic toxicity of antileishmanial drugs.
Paromomycin (Armijos et al. 2004) and imiquimod (Arevalo et al.
2001) can be applied topically in localized leishmaniasis.
In recent years, natural products have been a good source for
researchers in search of bioactive substances. Although prospects
for the cure of leishmaniasis are still uncertain, the development
of new extraction techniques and identiﬁcation of new and pow-
erful drugs from plants are contributing to this effect (Carvalho
and Ferreira 2001). Certain molecules isolated from natural sources
represent a major breakthrough in the search for new antiproto-
zoal drugs, since there is urgent need for a new era of innovative
medicines (Rocha et al. 2005).
Some species of the genus Calophyllum (Clusiaceae) are used
against several diseases. Researchers have shown that these plants
have cytotoxic activity, inhibition of HIV-1 reverse transcrip-
Open access under the Elsevier OA license.tase, antisecretory and cytoprotective properties, antinociceptive,
molluscicidal, and antimicrobial effects, due to the presence of
coumarins, xanthones, ﬂavonoids, and triterpenes (Noldin et al.
2006). The compound mammea A/BB is a coumarin-type mammea
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uriﬁed from leaves of Calophyllum brasiliense Camb. Previous stud-
es showed in vitro activity against L. amazonensis (Brenzan et al.
007) and Trypanosoma cruzi (Reyes-Chilpa et al. 2008).
The present study experimentally evaluated the in vivo activity
f (−) mammea  A/BB, in a BALB/c murine model infected with L.
mazonensis Josefa strain.
aterials and methods
lant material
The leaves of C. brasiliense were collected and identiﬁed by
r. Maria Claudia M.  Young on Cardoso Island, July 2000, in the
tate of São Paulo, Brazil. After authentication, a voucher specimen
SP 363818) was deposited at the Herbarium of the Instituto de
otânica de São Paulo, São Paulo, Brazil. The botanical material was
ven-dried, ground in a knife grinder and then stored in a dry dark
ocation at room temperature.
xtraction and puriﬁcation of compound (−) mammea A/BB
Extraction from leaf powder (7590 × g) was done after exhaus-
ive maceration in ethanol:water (90:10) at room temperature.
he extract was ﬁltered, and evaporated under vacuum at
0 ◦C to remove the organic solvent and to obtain an aque-
us extract and a residue. A dark-green residue from the crude
xtract was solubilized in dichloromethane, and the solvent was
hen completely evaporated at room temperature to yield a
ichloromethane extract (238 g). Next, this extract was  subjected to
hromatography in a vacuum silica–gel column 60 (70–230 mesh)
ith hexane, hexane–dichloromethane (50:50), dichloromethane,
ichloromethane–ethyl acetate (90:10–50:50), ethyl acetate,
ethanol, and ﬁnally methanol–water (90:10). Subsequently,
he hexane fraction (38.5 g) was further chromatographed
n a silica–gel column chromatograph and eluted with hex-
ne, hexane–dichloromethane (98:2–50:50), dichloromethane,
ichloromethane–ethyl acetate (98:2–50:50), ethyl acetate, and
ethanol. This procedure yielded the compound (−) mammea  A/BB
500 mg)  as described in previous studies (Brenzan et al. 2007,
008).
tructure elucidation
The structure of the isolated compound was  elucidated by
hromatography-mass spectrometry (Micromass Quattro LC);
uclear magnetic resonance (NMR; Gemini 2000 BB; Varian), 1H
MR  (300 MHz), and 13C NMR  (75.5 MHz), DEPT, COSY (400 MHz),
MBC, and HSQC analysis in CDCl3; infrared analysis (Bomem-MV
00; Hartmann & Braun-Michelson); and UV analysis (CARY 1E UV-
is; Varian). The ˛D was  obtained with a Perkin-Elmer Model 241
olarimeter at 20 ◦C at 589 nm,  using CH2Cl2, and by comparison
ith literature data (Gasparotto-Júnior et al. 2005).
arasites
The MHOM/BR/75/Josefa strain of L. amazonensis, originally iso-
ated from a human case of diffuse CL by C.A. Cuba-Cuba (University
f Brasília, Brasília, Distrito Federal, Brazil) was used in the present
tudy. The promastigotes were grown at 28 ◦C in Warren’s medium
brain–heart infusion plus hemin and folic acid) supplemented with
0% heat-inactivated fetal bovine serum in a tissue ﬂask. Parasites
ere centrifuged (2000 × g, 10 min), and washed three times in
hosphate buffered saline (PBS – 0.01 M,  pH 7.2) for use.ne 19 (2012) 1196– 1199 1197
Animals
The in vivo assay was carried out in male BALB/c mice weighing
approximately 20 g and 4 weeks of age. This study was conducted
according to ethical standards, and the experimental protocol (no.
013/2010) was  approved by the Animal Ethics Committee of the
Universidade Estadual de Maringá.
Infection
Animals were infected by subcutaneous inoculation with 107
infective promastigotes of L. amazonensis (late-log phase of growth)
in the left hind footpad. Footpad swelling was  monitored by serial
weekly measurements, for 30 days, of footpad thickness with the
help of a digital pachymeter. Animals were kept under conventional
conditions with free access to food (Nuvilab® Cr1) and water. The
groups were housed in groups of ﬁve in plastic cages in controlled
environmental conditions (12:12 h light/dark cycle and 22 ± 2 ◦C
room temperature).
In vivo evaluation of (−) mammea A/BB
After 8 weeks, lesions of measurable size were developed.
Cages were randomly sorted to receive different treatments.
The six groups were distributed as follows: group I: non-
infected control, group II: infected control, group III: reference
drug n-methylglucamine antimoniate (Glucantime®, Aventis
Pharma Ltda) dissolved in PBS and administered intramuscularly
(100 mg/kg/d, corresponding to 27 mg/kg/d of pentavalent anti-
mony), group IV: (−) mammea  A/BB dissolved in dimethylsulfoxide
(DMSO) and PBS administered intramuscularly (18 mg/kg/d), group
V: (−) mammea  A/BB 0.2% in a non-ionic base administered topi-
cally, group VI: DMSO (9%) control, administered intramuscularly.
Treatments were administered daily. The ﬁnal result was  expressed
as an increase in footpad thickness measured with a pachymeter,
which is expressed as the degree of swelling, subtracting the value
of the paw inoculated with the parasites from the value of the con-
trol footpad. The lesion size and the weight of mice were measured
every week during a period of 30 days.
Brenzan et al. (2010) showed that each mg  of dichloromethane
extract contained 20.6 ± 0.9 g of (−) mammea A/BB. Combined
with data from the study of Honda et al. (2010),  a correlation was
performed to estimate the concentration to be used in the topical
treatment in this study. For intramuscular treatment, the concen-
tration was  based on the recommendation of the manufacturer
of Glucantime® for a concentration of pentavalent antimony of
10–20 mg/kg/d for CL.
Histopathology
After 30 days, the mice were killed in a CO2 chamber. Liver,
spleen, lung, testicles, esophagus, kidney, heart, duodenum, and
stomach were washed in PBS, ﬁxed in Bouin’s solution, and pro-
cessed for histopathology by parafﬁn inclusion. Blocks were cut at
7 m thickness in a microtome (Leica Microsystems Inc., Germany),
mounted on slides and stained with hematoxylin–eosin.
Statistical analysis
For the statistical analysis in biological assays, means ± standard
deviation (SD) were calculated by the Microsoft Ofﬁce Excel 2007
software and the data were processed using Statistics 8.0®. Multiple
comparisons between groups were made with a one-way analysis
of variance (ANOVA) followed by Dunnet and Tukey tests. p values
1198 T.S. Tiuman et al. / Phytomedicine 19 (2012) 1196– 1199
Fig. 1. In vivo activity of (−) mammea A/BB in BALB/c mice infected by Leishmania amazonensis. After 8 weeks from infection, the animals were treated daily during 30 days
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tnd  the development of paw lesions was observed. (A) Group I: non-infected control
oute  (100 mg/kg/d); (D) group VI: DMSO (9%) control administered by intramuscul
F)  group V: (−) mammea  A/BB 0.2% administered topically.
f less than 0.05 were considered signiﬁcant and are represented
y an asterisk.
esults and discussion
So far, there is no ideal treatment for leishmaniasis. Plant-
erived substances of various structural classes have been
xtensively demonstrated to show antileishmanial activity and are
romising leads for the development of new medicines (Polonio
nd Efferth 2008).
Previously, Brenzan et al. (2007) reported that the compound
−) mammea  A/BB isolated from C. brasiliense showed in vitro activ-
ty against promastigote and amastigote forms of L. amazonensis,
nhibiting 50% growth at concentrations of 3.0 and 0.88 g/ml,
espectively. Later, Honda et al. (2010) demonstrated that mice
nfected with L. amazonensis had a decrease in footpad lesions when
reated topically with 10% dichloromethane extract or intraperi-
oneally with 100 mg/kg and 200 mg/kg of the hexane fraction of
. brasiliense.  Taken together, these studies encouraged us to apply
he isolated compound (−) mammea  A/BB in the treatment of mice
xperimentally infected with leishmaniasis.
The infection with L. amazonensis promastigotes in the foot-
ad of BALB/c mice induced a progressive increase in the lesion
ize in all the mice. After 8 weeks, the treatment was started and
ntreated animals (Fig. 1B) and the DMSO controls (Fig. 1D) devel-
ped larger lesions with progressive disease. In contrast, animals
reated with (−) mammea  A/BB, either intramuscularly (Fig. 1E)oup II: infected control; (C) group III: reference drug Glucantime® by intramuscular
ction; (E) group IV: (−) mammea A/BB administered intramuscularly (18 mg/kg/d);
or topically (Fig. 1F), showed control of the Leishmania infection.
Animals treated with the reference drug Glucantime® showed sim-
ilar results (Fig. 1C). Non-infected control group presented normal
footpad (Fig. 1A).
The untreated animals developed a characteristic lesion that
may present a secondary bacterial infection. No occurrence of sec-
ondary bacterial infection was observed in the treated animals. This
can be due to the antibacterial activity of mammea-type coumarin
derivatives. Mammea  A/BA, mammea  A/AA, mammea B/BB and
mammea  B/BA were active against methicillin-sensitive and -
resistant Staphylococcus aureus (Ouahouo et al. 2004; Yasunaka
et al. 2005). On the other hand, mammea  A/BA + A/BB, and mam-
mea C/OA + C/OB also reduced the growth of S. aureus,  as well as S.
epidermidis and Bacillus subtilis (Reyes-Chilpa et al. 2004).
This isolated compound from C. brasiliense showed ther-
apeutic potential, and a signiﬁcant difference (p < 0.05) in
the average lesion size was  observed in mice treated with
Glucantime® (1.36 ± 0.81 cm), (−) mammea  A/BB intramuscularly
(1.64 ± 0.8 cm)  and (−) mammea A/BB topically (1.32 ± 0.57 cm),
when compared with untreated animals (4.08 ± 1.31 cm). No
signiﬁcant difference was observed when (−) mammea A/BB intra-
muscularly or topically was compared to the positive control
Glucantime® (Fig. 2).With respect to animal average weight during the experiment,
the treated group (groups III, IV and V) showed no signiﬁcant dif-
ference (p < 0.05) when compared with the untreated group (group
II).
T.S. Tiuman et al. / Phytomedici
Fig. 2. Mean lesion size of footpads of mice treated for 30 days with Glucantime and
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(accessed 13.02.11).−)  mammea  A/BB intramuscularly (IM) and topically. Each column represents the
hickness of the infected footpad minus that of the uninfected contralateral footpad.
p  < 0.05 compared to the control group.
An incisional biopsy of all animals was taken for pathologic
valuation. All organs appeared healthy. The histopathological
valuation of liver, spleen, lung, testicles, esophagus, kidney, heart,
uodenum, and stomach did not reveal any distinct compound-
elated changes. No changes in behavior were observed in all groups
f mice.
Taken together, the results of all studies involving antileishma-
ial activity of C. brasiliense suggest that the active compound in
he dichloromethane crude extract is (−) mammea A/BB. Natural
roducts are undoubtedly valuable as a source of new medicinal
gents for infectious diseases. Few compounds of natural origin
ave been proven to be effective against CL infection through in
ivo studies. Intralesional injections of (+) usnic acid reduced sig-
iﬁcantly the weight lesions and the parasite loads in BALB/c mice
ootpads infected with L. amazonensis (Fournet et al. 1997). A signif-
cant decrease in the parasite burden and lesion size was observed
n the L. amazonensis-infected mice treated topically or intrarectally
ith limonene (Arruda et al. 2009).
An alternative approach to a dermatological problem such as
L is a topical formulation. The advantages of topical treatment
re the few adverse effects, better compliance by the patient, and
educed costs. Development of topical drugs is underway to inves-
igate some antileishmanial drugs by increasing the absorption of
he vehicle and their effect on percutaneous absorption and reten-
ion or drug release at the sites of infection in the dermis (Garnier
nd Croft 2002).
onclusion
Treatment of leishmaniasis remains a challenge that urgently
equires a solution and further research to obtain more potent and
elective drugs. Summed up, the results obtained here suggest that
t is important that in vitro tests be validated in animal studies.
herefore, it is reasonable to assume that the use of (−) mam-
ea  A/BB in the treatment of leishmaniasis ulcerations is truly
ffective in controlling L. amazonensis dissemination. The potent
eishmanicidal activities of certain chemically deﬁned molecules
solated from natural sources have become increasingly important
n the search for new antiprotozoal agents at a time when there is
n urgent need for a new group of innovative medicines.cknowledgements
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